

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/568,711
Confirmation Number	4660
Filing Date	February 17, 2006
First Named Inventor	Hidegori URATA
Art Unit	1611
Examiner Name	Joseph S. Kudla
Attorney Docket Number	Q93208

### U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

### U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	1312379	EP	A	2003-05-21	Takeda Chemical Industries Lt		
	2	0132621	WO	A	2001-05-10	Wakunaga Pharma Co Ltd.		
	3	1192949	EP	A	2002-04-03	Suntory Ltd; Daiichi Suntory Pharma Co Ltd		
	4	1211249	EP	A	2002-06-05	Santen Pharma Co Ltd.		
	5	03018061	WO	A	2003-03-06	Teijin Ltd		
	6	1249450	EP	A	2002-10-16	Teijin Ltd, Teijin Pharma Ltd		
	7	1097926	EP	A	2001-05-09	Teijin Ltd		
	8	1099690	EP	A	2001-05-16	Shionogi & Co		
	9	0936216	EP	A	1999-08-18	Nippon Kayaku KK		
	10	0940400	EP	A	1999-09-08	Yoshitomi Pharmaceutical Mitsubishi Pharma Corp		
	11	1325920	EP	A	2003-07-09	Toa Eiyo Ltd		

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	1	INOUE Y ET AL, Impaired glucose metabolism in human chymase transgenic mouse, Journal of Hypertension, Current Science, Philadelphia, PA, US, vol. 22 no. Suppl. 1, February 1, 2004 page s49, XP009115432	
	2	IZUMI K ET AL, "ACE sogaiyaku ni yoru insulin teikosel kaizen no mechanism/ACE INHIBITOR, INSULIN RESISTANCE, ANGIOTENSIN II TYPE 1 RECEPTOR, BRADYKININ B2 RECEPTOR " NAIBUNPI TONYOBYOKA-ENDOCRINOLOGY AND DIABETOLOGY, KAGAKU HYOROMNS, Tokyo, JP vol. 12, no. 4, April 1, 2001 pgs 391-397, XP002995619	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	3	MASAKI HIDEKAZU ET AL, "Structure-activity relationship of benzo [b] thiophene-2-sulfonamide derivatives as novel human chymase inhibitors". Bioorganic & Medical Chemistry Letters, vol. 13, no. 22, November 17, 2003 pages 4085-4088, XP002523990	
	4	AKAHOSHI F ET AL., "Non-peptidic inhibitors of human chymase. Synthesis structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1, 6-dihydropyrimidine-containing trifluoromethyl ketones." Bioorganic & Medicinal Chemistry, February 2, 2001, vol. 9, no. 2, pages 301-315, XP002523991	
	5	HUANG XIAO R ET AL., "Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotension II-mediated diabetic renal and vascular disease." Journal of The American Society of Nephrology, vol. 14, no. 7, July 2003, pages 1738-1747, XP002524027	
	6	KUEHN L ET AL., "Changes in proteinase/proteinase inhibitor levels in rat skeletal muscle tissue during diabetes and fasting" Biological Chemistry Hoppe-Seyler, Walter DE Gruyter, Berlin, DE, vol. 369, no. suppl, May 1, 1988, pages 299-305, XP009115424	
	7	European Search Report dated June 23, 2009 for EP Application No. 04772291.3-2123	

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.